ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 075,68
0,99%
Dow Jones
38 860,89
0,02%
DAX
18 430,05
1,42%
Brent Oil
83,145
-0,40%
Bitcoin
62 995,98
-0,27%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Mirati Therapeutics Inc (MRTX)

  7. Mirati Therapeutics Inc (MRTX) Actualités

MRTX Mirati Therapeutics Inc

58,70
0,00 (0,00%)
Dernière mise à jour : 02:00:00
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Mirati Therapeutics Inc MRTX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 58,70 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
58,70
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
14/2/202420:51EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202415:13EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
02/2/202422:05EDGAR2Form 15-12G - Securities registration termination [Section..
25/1/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
24/1/202402:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202402:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202402:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202402:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202402:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202402:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202402:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/1/202415:31EDGAR2Form S-8 POS - Securities to be offered to employees in..
23/1/202415:30EDGAR2Form POSASR - Post-effective Amendment to an automatic shelf..
23/1/202415:28EDGAR2Form POS AM - Post-Effective amendments for registration..
23/1/202415:27EDGAR2Form POS AM - Post-Effective amendments for registration..
23/1/202414:48EDGAR2Form 8-K - Current report
18/1/202422:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/1/202422:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/1/202414:00PRNUSEuropean Commission Approves KRAZATI (adagrasib) as a..
09/1/202423:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202423:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202400:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202400:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202400:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202400:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202423:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202423:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202322:05EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
22/12/202314:02DJFRBristol Myers Squibb va acquérir Karuna Therapeutics pour 14..
19/12/202322:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202313:30EDGAR2Form 8-K - Current report
14/12/202323:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202322:30EDGAR2Form 8-K - Current report
06/12/202314:29EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
01/12/202322:43EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
24/11/202322:45EDGAR2Form 8-K - Current report
15/11/202314:49EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
10/11/202313:30PRNUSMirati Therapeutics Receives Positive Opinion from CHMP for..
06/11/202314:05EDGAR2Form 8-K - Current report
06/11/202314:00PRNUSMirati Therapeutics Reports Third Quarter 2023 Financial..
06/11/202313:08EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/11/202322:19PRNUSMirati Therapeutics Receives Approval from the MHRA for..
02/11/202312:30EDGAR2Form DEFM14A - Definitive proxy statement relating to merger..
02/11/202312:30GLOBEKura Oncology and Mirati Therapeutics Enter into Clinical..
23/10/202323:31EDGAR2Form PREM14A - Preliminary proxy statements relating to..
17/10/202322:00PRNUSMirati Presents Late-Breaking Results Evaluating the..
11/10/202313:31EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
10/10/202313:35EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
10/10/202313:33EDGAR2Form 8-K - Current report

Dernières Valeurs Consultées

NASDAQ
MRTX
Mirati Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés